Cema-cel cell therapy after first treatment for large B-cell lymphoma with remaining cancer traces
Tests cema-cel versus observation in adults with large B-cell lymphoma and traces of remaining disease.
Key facts
- Who runs it
- Allogene Therapeutics
- Where
- Atlanta, Augusta, Austin, Baltimore, Berkeley, Bethesda, Boston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbia, Dallas, Duarte, Durham, East Brunswick, Eugene, Fairfax, Fort Wayne, Gilbert, Hackensack, Hot Springs, Houston, Indianapolis, Kansas City, Lexington, Lone Tree, Los Angeles, Louisville, Miami, Minneapolis, Nashville, New Brunswick, New York, Newark, Norfolk, Orlando, Philadelphia, Pittsburgh, Portland, Rochester, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, Seattle, Sioux Falls, Springfield, St Louis, Tampa, Tyler, and Washington D.C., United StatesSee the 64 sitesAlso in 3 other countries, 22 sites
- Trial code
- Registry title
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 250 people, planned
- Started
- 18 Jun 2024
- Expected to end
- Dec 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- cemacabtagene ansegedleucel
- Fludarabine
- Cyclophosphamide
- Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who finished first-line treatment for large B-cell lymphoma, responded well, but still have tiny traces of lymphoma found by a special blood test (MRD). It compares cema-cel CAR T cells with observation.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Large B-cell lymphoma (including diffuse large B-cell, high-grade B-cell, and primary mediastinal B-cell lymphoma) confirmed by pathology, with a complete or partial response after first-line therapy and a positive MRD test
- Earlier treatment
- Must have finished a full course of standard first-line therapy (for example R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) and had no additional lines of therapy. Must not have had anti-CD19 targeted therapy.
- Biomarker or test result
- Positive Foresight CLARITY IUO MRD test, powered by PhasED-Seq
Main reasons for not taking part
- Lymphoma that has involved the central nervous system, or transformed from another cancer, or T-cell/histiocyte rich large B-cell lymphoma
- Earlier treatment with anti-CD19 targeted therapies
- Anti-cancer treatment, including radiation, after the end-of-treatment PET/CT scan or MRD testing
- Active and clinically significant autoimmune disease, or active infection needing systemic treatment
- Another primary cancer or bone marrow disorder within 3 years before joining
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- LBCL per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma histologically confirmed by pathology report
- Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) as intended. Participants cannot have received additional lines of therapy
- Participant achieved CR, or PR suitable for observation, at the end of first line therapy based on PET/CT evaluation
- Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, is positive
- Adult participants ≥18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Adequate hematological, renal, hepatic, pulmonary, and cardiac function
- Non-hematologic toxicities related to prior therapy must be recovered to baseline or grade ≤1
Who cannot take part
- Prior treatment with anti-CD19 targeted therapies
- History of another primary malignancy or bone marrow disorder (e.g., myelofibrosis, smoldering multiple myeloma) within 3 years prior to enrollment
- LBCL with history of central nervous system involvement, transformed from other malignancy (e.g., transformed follicular lymphoma or marginal zone lymphoma, Richter's transformation), or T-cell/histiocyte rich LBCL
- Anti-cancer treatment, including radiation, after end of treatment PET/CT and/or MRD testing is performed
- Active and clinically significant autoimmune disease
- Active systemic bacterial, fungal, or viral infections requiring systemic treatment
Where in United States
Also in 3 other countries, 22 sites
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesContact: Allogene Therapeutics, IncNo longer taking part
- Augusta University, Georgia Cancer CenterAugusta, United StatesContact: Locke Bryan, MD (principal investigator)Taking people
- Texas Oncology - Central SouthAustin, United StatesContact: Jason Melear, MD (principal investigator)Taking people
- University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United StatesContact: Jean Yared, MD (principal investigator)Taking people
- Alta Bates Summit Medical CenterBerkeley, United StatesContact: Oleg Krijanovski, MD (principal investigator)Taking people
- The Center for Cancer and Blood DisordersBethesda, United StatesContact: Ralph Boccia, MD (principal investigator)Taking people
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Michael Leukam, MD (principal investigator)Taking people
- Massachusetts General HospitalBoston, United StatesContact: Jeremy Abramson, MD (principal investigator)Taking people
- Novant Health Cancer Institute HematologyCharlotte, United StatesContact: Alan Skarbnik, MD (principal investigator)Taking people
- University of VirginiaCharlottesville, United StatesContact: Indumathy Varadarajan, MD (principal investigator)Taking people
- Northwestern University Feinberg School of MedicineChicago, United StatesContact: Reem Karmali, MD (principal investigator)Taking people
- Rush University Medical CenterChicago, United StatesContact: Sunita Nathan, MD (principal investigator)Taking people
- Oncology Hematology Care - KenwoodCincinnati, United StatesContact: Ahmed Galal, MD (principal investigator)Taking people
- University of Cincinnati Medical CenterCincinnati, United StatesContact: Tahir Latif, MD (principal investigator)Taking people
- Cleveland ClinicCleveland, United StatesContact: Paolo Caimi, MD (principal investigator)Taking people
- University of Missouri - Ellis Fischel Cancer CenterColumbia, United StatesContact: Gerhard Hildebrandt, MD (principal investigator)Taking people
- Texas Oncology - Dallas Fort WorthDallas, United StatesContact: Houston Holmes, MD (principal investigator)Taking people
- City of HopeDuarte, United StatesContact: Geoffrey Shouse, MD (principal investigator)Taking people
- Duke Blood Cancer CenterDurham, United StatesContact: Mitchell Horwitz, MD (principal investigator)Taking people
- Astera Cancer CareEast Brunswick, United StatesContact: Edward Licitra, MD (principal investigator)Taking people
- Oncology Associates of OregonEugene, United StatesContact: Jeff Sharman, MD (principal investigator)Taking people
- Virginia Cancer SpecialistsFairfax, United StatesContact: Mitul Gandhi, MD (principal investigator)Taking people
- Fort Wayne Medical Oncology and HematologyFort Wayne, United StatesContact: Sunil Babu, MD (principal investigator)Taking people
- Banner MD Anderson Cancer CenterGilbert, United StatesContact: Matthew Ulrickson, MD (principal investigator)Taking people
- John Theurer Cancer CenterHackensack, United StatesContact: Lori Leslie, MD (principal investigator)Taking people
- Genesis Cancer and Blood InstituteHot Springs, United StatesContact: Stephen Divers, MD (principal investigator)Taking people
- MD Anderson Cancer CenterHouston, United StatesContact: Jason Westin, MD (principal investigator)Taking people
- Indiana Blood and Marrow TransplantationIndianapolis, United StatesContact: Anand Tandra, MD (principal investigator)Taking people
- IU Simon Comprehensive Cancer CenterIndianapolis, United StatesContact: Varun Mittal, MD (principal investigator)Taking people
- MidAmerica Cancer CareKansas City, United StatesContact: Jaswinder Singh, MD (principal investigator)Taking people
- The University of Kansas HospitalKansas City, United StatesContact: Allogene Therapeutics, IncNo longer taking part
- University of Kentucky Medical CenterLexington, United StatesContact: Chaitanya Iragavarapu, MD (principal investigator)Taking people
- Rocky Mountain Cancer CentersLone Tree, United StatesContact: John Burke, MD (principal investigator)Taking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Akil Merchant, MD (principal investigator)Taking people
- University of California, Los AngelesLos Angeles, United StatesContact: Sven DeVos, MD (principal investigator)Taking people
- Norton Cancer InstituteLouisville, United StatesContact: Don Stevens, MD (principal investigator)Taking people
- University of Louisville Health Brown Cancer CenterLouisville, United StatesContact: Hassaan Yasin, MD (principal investigator)Taking people
- Miami Cancer Institute at Baptist Health, Inc.Miami, United StatesContact: Yuliya Linhares, MD (principal investigator)Taking people
- University of Minnesota Medical CenterMinneapolis, United StatesContact: Veronica Bachanova, MD (principal investigator)Taking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Andrew Jallouk, MD (principal investigator)Taking people
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesContact: Matthew Matasar, MD (principal investigator)Taking people
- Columbia University Irving Medical Center and New York-Presbyterian HospitalNew York, United StatesContact: Ran Reshef, MD (principal investigator)Taking people
- Medical Oncology Hematology ConsultantsNewark, United StatesContact: Jamal Misleh, MD (principal investigator)Taking people
- Virginia Oncology Associates - NorfolkNorfolk, United StatesContact: Gary Simmons, MD (principal investigator)Taking people
- Advent Health Cancer InstituteOrlando, United StatesContact: Rushang Patel, MD (principal investigator)Taking people
- Orlando Health Cancer InstituteOrlando, United StatesContact: Abhishek Chilkulwar, MD (principal investigator)Taking people
- Fox Chase Cancer CenterPhiladelphia, United StatesContact: Rashmi Khanal, MD (principal investigator)Taking people
- West Penn HospitalPittsburgh, United StatesContact: Prerna Mewawalla, MD (principal investigator)Taking people
- Oregon Health and Science UniversityPortland, United StatesContact: Richard Maziarz, MD (principal investigator)Taking people
- University of Rochester Medical CenterRochester, United StatesContact: Patrick Reagan, MD (principal investigator)Taking people
- University of California Davis Comprehensive Cancer CenterSacramento, United StatesContact: Naseem Esteghamat, MD (principal investigator)Taking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesContact: Lindsey Fitzgerald, MD (principal investigator)Taking people
- Intermountain Health LDS HospitalSalt Lake City, United StatesContact: Bradley Hunter, MD (principal investigator)Taking people
- Texas Transplant InstituteSan Antonio, United StatesContact: Nosha Farhadfar, MD (principal investigator)Taking people
- University of California San DiegoSan Diego, United StatesContact: Ayad Hamdan, MD (principal investigator)Taking people
- University of California San FranciscoSan Francisco, United StatesContact: Michael Spinner, MD (principal investigator)Taking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Ryan Lynch, MD (principal investigator)Taking people
- Swedish Cancer InstituteSeattle, United StatesContact: Matthew Schwede, MD (principal investigator)Taking people
- Avera Cancer InstituteSioux Falls, United StatesContact: Waqas Jehangir, MD (principal investigator)Taking people
- Oncology Hematology AssociatesSpringfield, United StatesContact: Robert Ellis, MD (principal investigator)Taking people
- Washington University School of Medicine - Siteman Cancer CenterSt Louis, United StatesContact: Nancy Bartlett, MD (principal investigator)Taking people
- Moffitt Cancer CenterTampa, United StatesContact: Frederick Locke, MD (principal investigator)Taking people
- Texas Oncology - TylerTyler, United StatesContact: Habte Yimer, MD (principal investigator)Taking people
- MedStar Georgetown University HospitalWashington D.C., United StatesContact: Kieron Dunleavy, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.
Read full original descriptionShow less
In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide.
Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
The 2 groups in the trial
- cemacabtagene ansegedleucelTreatment being tested
Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide.
Treatment: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
- ObservationOther group
Participants do not receive any study treatments. They are observed as per the current standard of care.
Treatment: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
- Plain-language title
- Cema-cel cell therapy after first treatment for large B-cell lymphoma with remaining cancer tracesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 October 2026